Publications by authors named "Stacie Lindsey"
What Is This Summary About?: Researchers wanted to study whether the research drug zanidatamab could help people with a type of cancer called biliary tract cancer. In some people, biliary tract cancer cells make extra copies of a gene called HER2 (also called ERBB2). This is known as being HER2-amplified.
View Article and Find Full Text PDFTo understand cholangiocarcinoma symptoms, diagnosis and treatment experience from the patient and caregiver perspective, including cholangiocarcinoma's impact on daily life, quality of life (QoL) and mental health. Patients and caregivers participated in two online surveys (in partnership with the Cholangiocarcinoma Foundation). The patient survey data (n = 707) show a substantial impact of cholangiocarcinoma on QoL and mental health, with 34% of patients reporting symptoms consistent with moderately severe/severe depression.
View Article and Find Full Text PDFPurpose: Increased awareness of the distinct tumor biology for adolescents and young adults (AYAs) with cancer has led to improvement in outcomes for this population. However, in cholangiocarcinoma (CCA), a paucity of data exist on the AYA population. To our knowledge, we present the largest study to date on AYA disease biology, treatment patterns, and survival outcomes in CCA.
View Article and Find Full Text PDFBackground: Treatment patterns for intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) differ, but limited studies exist comparing them. This study examines differences in molecular profiling rates and treatment patterns in these populations, focusing on use of adjuvant, liver-directed, targeted, and investigational therapies.
Methods: This multicenter collaboration included patients with ICC or ECC treated at 1 of 8 participating institutions.
Background And Aims: Biliary tract cancer (BTC) is a rare, lethal, heterogeneous group of cancers often diagnosed at an advanced stage. While gemcitabine plus cisplatin is the standard of care for first-line treatment of locally advanced or metastatic BTC, no globally accepted standard of care currently exists for second-line treatment of BTC following chemotherapy. However, the treatment landscape is evolving with approvals for therapies targeting actionable mutations.
View Article and Find Full Text PDFArticle Synopsis
- A study examined health-related quality of life (HRQoL) for patients with cholangiocarcinoma (CCA), revealing limited data on how experimental therapies impact patients' well-being.
- Of the 208 patients surveyed, those in clinical trials or receiving targeted therapy experienced similar physical and emotional health as those who weren't, but reported greater financial burden.
- The findings suggest that while new therapies do not harm overall well-being, they are associated with higher costs and limited accessibility, emphasizing the need to improve access and reduce financial strain on patients.
Article Synopsis
- - ASCO evaluated changes in care delivery, research, and regulation due to the COVID-19 pandemic and provided recommendations for future improvements as the situation stabilizes.
- - Their recommendations for clinical research target five goals to enhance accessibility, efficiency, and safety, including reducing administrative burdens and supporting a trained workforce.
- - For cancer care delivery, ASCO emphasized five goals focused on ensuring equitable access, supporting patient care resources, and expanding telemedicine options to improve overall cancer care quality.